Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Research & Development: 2022-2024

Historic Research & Development for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to $42.8 million.

  • Orchestra BioMed Holdings' Research & Development rose 20.97% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.3 million, marking a year-over-year increase of 29.72%. This contributed to the annual value of $42.8 million for FY2024, which is 26.56% up from last year.
  • Latest data reveals that Orchestra BioMed Holdings reported Research & Development of $42.8 million as of FY2024, which was up 26.56% from $33.8 million recorded in FY2023.
  • Orchestra BioMed Holdings' Research & Development's 5-year high stood at $42.8 million during FY2024, with a 5-year trough of $21.9 million in FY2022.
  • For the 3-year period, Orchestra BioMed Holdings' Research & Development averaged around $32.9 million, with its median value being $33.8 million (2023).
  • Data for Orchestra BioMed Holdings' Research & Development shows a peak YoY skyrocketed of 54.12% (in 2023) over the last 5 years.
  • Orchestra BioMed Holdings' Research & Development (Yearly) stood at $21.9 million in 2022, then surged by 54.12% to $33.8 million in 2023, then increased by 26.56% to $42.8 million in 2024.